Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ezaladcigene resoparvovec - Neurocrine Biosciences/Voyager Therapeutics

Drug Profile

Ezaladcigene resoparvovec - Neurocrine Biosciences/Voyager Therapeutics

Alternative Names: AAV-AADC; AAV-hAADC; AAV-hAADC-2; AAV-hAADC-gene-therapy - Voyager Therapeutics; AAV2-hAADC; AAV2-hAADC - Voyager Therapeutics; Aromatic-L-amino-acid-decarboxylase-gene-therapy; AV 201; GZ 404477; NBIb-1817; VY AADC01; VY AADC02; VY-AADC

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California at San Francisco
  • Developer National Institutes of Health (USA); University of California at San Francisco; Voyager Therapeutics
  • Class Antiparkinsonians; Gene therapies
  • Mechanism of Action Aromatic-L-amino-acid decarboxylase replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 10 Aug 2021 Voyager Therapeutics completes a phase I trial in Parkinson's disease in USA (NCT03065192)
  • 10 May 2021 Ezaladcigene resoparvovec is available for licensing as of 10 May 2021. https://www.voyagertherapeutics.com/contact/
  • 10 May 2021 Discontinued - Phase-I for Parkinson's disease (In children) in USA (Intrastriatal)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top